Growth retardation associated with a novel DNMT3A variation in a Chinese boy: A case report

Lixia Wang,Weizhong Yang,Hongwen Zhang
DOI: https://doi.org/10.22541/au.169538591.18558522/v1
2023-01-01
Abstract:Abstract Background The human gene DNMT3A (DNA methyltransferase 3 alpha) is involved in DNA de novo methylation essential for genome regulation and development. Pathogenic variants in DNMT3A are most commonly associated with variable overgrowth (such as Tatton-Brown-Rahman Syndrome, TBRS), intellectual disability, autism spectrum disorder (ASD) and acute myeloid leukemia (AML). We identified a de novo DNMT3A variant in a Chinese boy with growth retardation. Case presentation A 2.8-year boy was hospitalized with a complaint of growth retardation for 24 months. He was born at 38 weeks of gestation. He showed obviously growth retardation since 3 months of age later, including weight and height. His motor and intellectual developmental milestone were slightly delayed. He began to rise head and turn over at 4 months, sit at 6 months, crawl at 7 months and work at 18 months, respectively. He began to speak a single word at 12 months and could speak few words at 2 years. At admission at 2.8 years of age, his weight was 9.6 kg (< P 3 th ), height was 85.4 cm (< P 3 th ), and head circumference was 45.2 cm (< P 3 th ). He could run but could not jump with two feet, he could follow easy and simple instructions. Physical examination revealed no abnormal signs, especially no abnormal dysmorphic features. A de novo DNMT3A variant, c.911_913del (p.S304del), was identified using next-generation sequencing. His growth retardation was associated with DNMT3A variation. Conclusion We reported here the first case presented with growth retardation who was associated with a de novo DNMT3A variation in a Chinse boy. Our report has expanded on the clinical phenotype of the DNMT3A gene, which can also associated with growth retardation besides overgrowth.
What problem does this paper attempt to address?